AbbVie : ABBV

All AbbVie Articles

603 Articles

Chris Lange | Nov 12, 2018 at 10:10 AM EST

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

The October 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Nov 6, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, AMAG Pharma, Crocs, HCA, Kellogg, Kosmos Energy, Mylan, Pandora, Square and More

The top analyst upgrades, downgrades and initiations seen on Tuesday included AbbVie, AMAG Pharmaceuticals, Crocs, HCA, Kellogg, Kosmos Energy, Mylan,…

Chris Lange | Nov 2, 2018 at 10:23 AM EDT

AbbVie Little Changed Despite Big Bottom-Line Beat

AbbVie released its third quarter financial results before the markets opened on Friday. The pharma giant said that it had…

Paul Ausick | Nov 1, 2018 at 2:08 PM EDT

Encana, Hanesbrands Sink into Thursday’s 52-Week Low Club

Encana, Hanesbrands, Abbvie, and Annaly Capital Management all posted new 52-week lows Thursday.

Chris Lange | Oct 25, 2018 at 9:00 AM EDT

Major Pharma Short Sellers Hike Their Bets

The October 15 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Oct 25, 2018 at 7:10 AM EDT

Why Large Cap Pharmaceuticals Will Hold Up in a Bear Market

These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices…

Chris Lange | Oct 10, 2018 at 9:10 AM EDT

Short Sellers Run for Cover From Major Pharma

The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Jon C. Ogg | Oct 4, 2018 at 12:10 PM EDT

Rising Interest Rates and All, 13 Blue Chips Outyield 10-Year and 30-Year Treasuries

Here are 13 companies with solid dividends that currently yield more than both the 10-year Treasury note and the 30-year…

Chris Lange | Sep 26, 2018 at 8:50 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Sep 19, 2018 at 1:50 PM EDT

Should AbbVie Be More Concerned About Its California Case for Humira?

AbbVie shares took a dip on Wednesday after it was announced that the pharma giant would be facing a lawsuit…

Chris Lange | Sep 13, 2018 at 9:55 AM EDT

Short Sellers Back Off Major Pharma Stocks

The August 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 27, 2018 at 7:25 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Jon C. Ogg | Aug 22, 2018 at 11:10 AM EDT

Why Big Pharma Stocks May Offer Big Upside and Dividends for the Second Half of 2018

Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team…

Jon C. Ogg | Aug 15, 2018 at 11:50 AM EDT

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors.…

Chris Lange | Aug 10, 2018 at 9:50 AM EDT

Short Sellers Hike Bets in Major Pharma Stocks

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

1 … 19 20 21 22 23 … 41

AbbVie : ABBV

All AbbVie Articles

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

Top Analyst Upgrades and Downgrades: AbbVie, AMAG Pharma, Crocs, HCA, Kellogg, Kosmos Energy, Mylan, Pandora, Square and More

AbbVie Little Changed Despite Big Bottom-Line Beat

Encana, Hanesbrands Sink into Thursday’s 52-Week Low Club

Major Pharma Short Sellers Hike Their Bets

Why Large Cap Pharmaceuticals Will Hold Up in a Bear Market

Short Sellers Run for Cover From Major Pharma

Rising Interest Rates and All, 13 Blue Chips Outyield 10-Year and 30-Year Treasuries

Short Sellers Grow More Selective on Major Pharma Stocks

Should AbbVie Be More Concerned About Its California Case for Humira?

Short Sellers Back Off Major Pharma Stocks

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

Why Big Pharma Stocks May Offer Big Upside and Dividends for the Second Half of 2018

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Short Sellers Hike Bets in Major Pharma Stocks

Scott Bessent Recommends Social Security Cut Benefits “by 30.3%” for New Retirees as Trust Fund Collapse Accelerates

OpenAI IPO May Not Be Coming Anytime Soon, Veteran Journalist Says

Consumers See Inflation Falling as Long-Term Expectations Drop to 3.3%

Scott Bessent Recommends Social Security Cut Benefits "by 30.3%" for New Retirees as Trust Fund Collapse Accelerates

Consumers See Inflation Falling as Long-Term Expectations Drop to 3.3%

Scott Bessent Recommends Social Security Cut Benefits “by 30.3%” for New Retirees as Trust Fund Collapse Accelerates

OpenAI IPO May Not Be Coming Anytime Soon, Veteran Journalist Says

AbbVie : ABBV

All AbbVie Articles

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

Top Analyst Upgrades and Downgrades: AbbVie, AMAG Pharma, Crocs, HCA, Kellogg, Kosmos Energy, Mylan, Pandora, Square and More

AbbVie Little Changed Despite Big Bottom-Line Beat

Encana, Hanesbrands Sink into Thursday’s 52-Week Low Club

Major Pharma Short Sellers Hike Their Bets

Why Large Cap Pharmaceuticals Will Hold Up in a Bear Market

Short Sellers Run for Cover From Major Pharma

Rising Interest Rates and All, 13 Blue Chips Outyield 10-Year and 30-Year Treasuries

Short Sellers Grow More Selective on Major Pharma Stocks

Should AbbVie Be More Concerned About Its California Case for Humira?

Short Sellers Back Off Major Pharma Stocks

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

Why Big Pharma Stocks May Offer Big Upside and Dividends for the Second Half of 2018

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Short Sellers Hike Bets in Major Pharma Stocks

Scott Bessent Recommends Social Security Cut Benefits “by 30.3%” for New Retirees as Trust Fund Collapse Accelerates

OpenAI IPO May Not Be Coming Anytime Soon, Veteran Journalist Says

Consumers See Inflation Falling as Long-Term Expectations Drop to 3.3%

Featured Reads

Scott Bessent Recommends Social Security Cut Benefits "by 30.3%" for New Retirees as Trust Fund Collapse Accelerates

Consumers See Inflation Falling as Long-Term Expectations Drop to 3.3%